533,784 Shares in Stryker Corporation $SYK Acquired by Veritas Asset Management LLP

Veritas Asset Management LLP bought a new stake in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 533,784 shares of the medical technology company’s stock, valued at approximately $168,057,000. Stryker comprises 3.0% of Veritas Asset Management LLP’s investment portfolio, making the stock its 15th largest position.

Other large investors have also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the fourth quarter valued at $26,000. Sankala Group LLC bought a new stake in shares of Stryker during the 4th quarter worth $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker during the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker in the 4th quarter worth $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker in the 4th quarter worth $28,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

Shares of SYK opened at $338.80 on Friday. The business’s 50-day moving average is $324.61 and its 200-day moving average is $333.57. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market capitalization of $129.95 billion, a price-to-earnings ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the company posted $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Analysts Set New Price Targets

SYK has been the subject of a number of recent analyst reports. Citizens Jmp decreased their price target on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Evercore set a $350.00 price objective on shares of Stryker in a research note on Monday, July 6th. Royal Bank Of Canada decreased their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Barclays dropped their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Finally, Truist Financial boosted their price target on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Insider Transactions at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.